James B. Tananbaum Portfolio
Invests via Foresite Capital Management VI LLC | Managed by James B. Tananbaum
Invests via Foresite Capital Management VI LLC
Managed by James B. Tananbaum
Automatically Tracked
James B. Tananbaum Profile
Veteran life-sciences investor and founder-CEO known for building a crossover bio-focused investment platform that deploys patient capital across public and private companies.
James B. Tananbaum leads RA Capital, directing concentrated equity and venture investments in therapeutics, diagnostics and platform biotech, and serves on multiple corporate boards while positioning the firm between VC and long-only strategies to finance translational R&D and late-stage clinical value creation.
Veteran life-sciences investor and founder-CEO known for building a crossover bio-focused investment platform that deploys patient capital across public and private companies.
James B. Tananbaum leads RA Capital, directing concentrated equity and venture investments in therapeutics, diagnostics and platform biotech, and serves on multiple corporate boards while positioning the firm between VC and long-only strategies to finance translational R&D and late-stage clinical value creation.
Investment Philosophy & Strategy
Deploys patient, concentrated capital across public and private life-science companies, prioritizing therapeutics, diagnostics and platform biotech. Blends venture and crossover approaches to underwrite translational R&D and late-stage clinical value creation, favoring investments where scientific validation, regulatory path and clear clinical catalysts align. Time horizon is multi-stage and long, with active board engagement to derisk development and shape value inflection. Capital allocation emphasizes concentrated, conviction positions complemented by stage diversification and exit-ready public stakes. Risk discipline centers on technical due diligence, milestone-driven financing and portfolio sizing around asymmetric risk/reward.
Deploys patient, concentrated capital across public and private life-science companies, prioritizing therapeutics, diagnostics and platform biotech. Blends venture and crossover approaches to underwrite translational R&D and late-stage clinical value creation, favoring investments where scientific validation, regulatory path and clear clinical catalysts align. Time horizon is multi-stage and long, with active board engagement to derisk development and shape value inflection. Capital allocation emphasizes concentrated, conviction positions complemented by stage diversification and exit-ready public stakes. Risk discipline centers on technical due diligence, milestone-driven financing and portfolio sizing around asymmetric risk/reward.
Disclaimer: This Portfolio is derived from and computed based on publicly available data from SEC filings.
Gain and growth charts are calculated per selected timeframe:
38.41%
Gain +0.9%
Monthly
1.88%
Yearly
25.03%
Drawdown
41.61%
$454.56M
Equity
Holdings
$454.56M
Investment
$261.59M
$211.66M
Profit +$5.81M
Realized
$18.69M
Unrealized
$192.97M
Dividends
$0
Goals
Avg. 100% completed goals
Yearly
Gain > 5% 2026
Yearly
Gain < 20% 2026
Today
Compared To Yesterday
Gain
0.9%
Profit
$5.81M
Win %
66%
This Week
Compared To Last Week
Gain
1.26%
Profit
$5.67M
Win %
66%
This Month
Compared to last month
Gain
2.67%
Profit
$11.84M
Win %
66%
This Year
Compared to last year
Gain
8.7%
Profit
$26.26M
Win %
70%
OKUR OnKure Therapeutics Inc.
+5.83%
+$354,216.84 
HNGE Hinge Health Inc.
+3.69%
+$531,164 
JBIO Jade Biosciences Inc.
+2.22%
+$108,800 
AGIO Agios Pharmaceuticals Inc.
+2.07%
+$320,250 
ALMS Alumis Inc.
+2.04%
+$2.09M 
CRVS Corvus Pharmaceuticals Inc.
+2.01%
+$439,495.92 
NERV Minerva Neurosciences Inc.
+1.89%
+$168,861 
KYMR Kymera Therapeutics Inc.
+1.56%
+$196,801.91 
DNLI Denali Therapeutics Inc.
+1.34%
+$350,891.59 
CRNX Crinetics Pharmaceuticals Inc.
+1.28%
+$93,284.4 
ZURA Zura Bio Ltd.
+1.08%
+$18,000 
CGON CG Oncology, Inc.
+1.07%
+$1.41M 
ATAI AtaiBeckley Inc.
+0.51%
+$55,000 
CNTA Centessa Pharmaceuticals plc American Depositary Receipt
+0.11%
+$61,380.86 
Events
Loading...
Dividends
Dividend Analysis
Loading...
No Data
| Trades 52 | Longs Won 24/52 46% | Profit Factor 5.7 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $15.28M |
| Average Win $10.7M | Best Trade (Jun 15) $70.53M | Sharpe Ratio -7.19 |
| Average Loss -$1.61M | Worst Trade (Sep 29) -$7.95M | Z-Score -0.38 (29.56%) |
| Commissions $0 | Avg. Trade Length 7m 1w | Expectancy $4.07M |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | 0.04% | 0.39% | 3.1% | 19.38% |
| Consecutive Losing Trades | 282 | 254 | 226 | 198 | 169 | 141 | 113 | 85 | 56 | 28 |
Hover over the desired column for a detailed explanation.
Returns
Overall, MonthlyNo Data
Option values are updated at end of day.
No Data
No Data
Option values are updated at end of day.
No Data
No Data
No Data
No Data
